| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G/A |
| 10 Nov 2026 |
Form 4: Slattery Joseph P, Director
Sold 5,200 shares ($113K) |
| 10 Nov 2026 | SCHEDULE 13G |
| 09 Nov 2026 | 144 |
| 09 Nov 2026 | SCHEDULE 13G/A |
| 06 Nov 2026 | FORM 10-Q/A |
| 03 Nov 2026 |
Form 4: Dhingra Kapil, Director
Received 43,169 shares by exercise or conversion ($75.5K) · Sold 21,500 shares ($409K) |
| 03 Nov 2026 | 144 |
| 02 Nov 2026 | 144 |
| 30 Oct 2026 | 144 |
| 28 Oct 2026 | 144 |
| 28 Oct 2026 | 10-Q |
| 28 Oct 2026 |
8-K: Results of Operations and Financial Condition
TUDRIQEV first delivered to patients for advanced melanoma on October 6th |
| 16 Sep 2026 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders
CERTIFICATE OF AMENDMENT TO THE THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF REPLIMUNE GROUP, INC. (Pursuant to Section 242 of the General Corporation Law of the State of Delaware) |
| 24 Aug 2026 |
Form 4: Astley-Sparke Philip, Director
Gave 50,000 shares as a gift |
| 19 Aug 2026 |
Form 4: Hill Emily Luisa, Chief Financial Officer
Sold 9,256 shares ($132K) |
| 14 Aug 2026 | S-3ASR |
| 14 Aug 2026 | 10-Q |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 14 Aug 2026 |
8-K: Results of Operations and Financial Condition
TUDRIQEV™ in combination with nivolumab receives FDA accelerated approval and will launch within 60 days |
Loading...